A study led by scientists from INRAE, the Barcelona Institute for Global Health, Inserm, and the Université Sorbonne Paris Nord, has revealed that the time at which we eat could influence our risk of developing cardiovascular disease.
Lyon, Paris, France - 20th October 2022 - 6 pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates
Regulatory News: SpineGuard (FR0011464452 ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of
AMF-regulated(1) Adbio partners, an investment company dedicated to life sciences, has welcomed Inserm Transfert, a private subsidiary of the French National Institute of Health and Medical Research (Inserm) as an investor in its AFB Fund II. Click to read more.